Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment

Blood Reviews

Volumn 16, Issue 3, 2002, Pages 193-202

  Bellucci, S ^a   Caen, J ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Academie des Sciences   (France)

Author keywords

Glanzmann Thrombasthenia; Platelet alloimmunisation; IIb 3 integrin

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; DESMOPRESSIN; FIBRINOGEN RECEPTOR; GESTAGEN; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ALLOIMMUNITY; BLEEDING; DRUG CONTRAINDICATION; GENETIC IDENTIFICATION; GLANZMANN DISEASE; HERITABILITY; HISTORY OF MEDICINE; HUMAN; MENORRHAGIA; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTE TRANSFUSION; DISEASE MANAGEMENT; FEMALE; GENETICS; HISTORY; MALE; MUTATION;

DISEASE MANAGEMENT; FEMALE; HEMORRHAGE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MUTATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA;

EID: 0036729273     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00030-9     Document Type: Review

References (98)

1. Glanzmann's thrombasthenia
2. Glanzmann's thrombasthenia: The spectrum of clinical disease
3. Platelet-Vessel wall interaction: From the bedside to molecules
4. Inherited abnormalities of platelets
5. Hereditäre hämorrhagische thrombasthenic. Ein beitrag zur pathologie der blutplättchen
6. Le trouble d'adhésivité "in vivo" des plaquettes dans la maladie de Willebrand et les thrombasthénies de Glanzmann. Essai d'interprétation
7. Congenital bleeding disorders with long bleeding time and normal platelet count
8. Glanzmann's thrombasthenia
9. Human platelet activation in the absence of aggregation: Calcium-dependent phenomenon independent of thromboxane formation
10. An abnormal glycoprotein pattern in 3 cases of Glanzmann thrombasthenia
11. Specific roles for platelet surface glycoproteins in platelet function
12. Platelet membrane defects in Glanzmann's thrombasthenia: Evidence for decreased amounts of two major glycoproteins
13. Immunochemical evidence for protein abnormalities in platelets from patient with Glanzmann's thrombasthenia and Bernard-Soulier syndrome
14. 2+ and missing in Glanzmann's thrombasthenia
15. Determination of platelet antigens and glycoproteins in the human fetus
16. Epistaxis
17. A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel
18. Increased incidence of Glanzmann's thrombasthenia in Jordan compared with Scandinavia
19. Glanzmann's thrombasthenia in pregnancy: A case and review of the literature
20. Diffuse and severe digestive angiodysplasia in Bernard-Soulier syndrome. Improvement of intestinal bleeding by oestroprogestative therapy
21. International survey of patients with von Willebrand disease and angiodysplasia
22. Platelet aggregation is not necessary for occurrence of Raynaud phenomenon
23. Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin
24. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha (IIb) beta (3) (GPIIb/IIIa) and alpha (v) beta (3) receptors are not protected from atherosclerosis
25. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann's thrombasthenia in Israel
26. Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain
27. The evolution of megakaryocytes to platelets
28. Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes
29. 3) in human platelets and megakaryocytes reveals intracellular pool and labeling of the α granule membrane
30. Exposure of ligand-binding sites on platelet integrin alpha IIb/beta 3 by phosphorylation of the beta 3 subunit
31. Platelet membrane glycoproteins: Functions in cellular interactions
32. Integrin α, β, and platelet function
33. Binding of recombinant fibrinogen mutants to platelets
34. 3: De la biologie cellulaire aux médicaments antithrombotiques
35. Two-way of trafficking of membrane glycoproteins on thrombin activated human platelets
36. 3 binds prothrombin and influences its activation
37. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect
38. Inhibition of platelet-mediated, tissue factor induced thrombin generation by the mouse/human chimeric 7E3 antibody
39. Dissecting clot retraction and platelet aggregation
40. 3 integrins
41. Localization of thrombospondin in clots formed in situ
42. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor
43. The molecular genetics of Glanzmann's thrombasthenia
44. The molecular genetic basis of Glanzmannn thrombasthenia in the Iraqi-Jewish and Arab populations in Israel
45. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France. Identification of a new mutation on the α IIb gene
46. Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) and glycoprotein IIIa (beta3) genes
47. Inherited disorders of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome and other disorders
48. Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domain of GPIIb
49. E)GPIIb
50. A novel (288delC) mutation in exon 2 of GPIIb associated with type I Glanzmann's thrombasthenia
51. A naturally occuring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIb beta3
52. Molecular genetic analysis of a compound heterozgote for the glycoprotein (GP) IIb gene associated with Glanzmann's thrombasthenia: Disruption of the 674-787 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes
53. Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia
54. 3) Arg 214 by Trp
55. Glanzmann thrombasthenia. Cooperation between sequence variants in Cis during splice selection
56. 327 for β3 integrin subunit association
57. Homozygous Cys542-Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia
58. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa(β3) in a Chinese patient with Glanzmann's thrombasthenia
59. 162 > Leu mutation within glycoprotein (GP) IIIa (integrin β3), results in an unstable αIIbβ3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia
60. Type II Glanzmann thrombasthenia (GT) in a compound heterozygote for the glycoprotein (GP) IIIa gene associating two novel mutations, a stop codon (Arg 216) and a Cys598Tyr substitution in mature GPIIIa
61. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbβ3) integrin locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype
62. A Leu262Pro mutation in the integrin beta(3) subunit results in an alpha(IIb)-beta(3) complex that binds fibrin but not fibrinogen
63. A Vall93Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand
64. Missense mutations in the beta(3) subunit have a different impact on the expression and function between alpha (IIb)beta(3) and alpha(v)beta (3)
65. A naturally occuring point mutation in the beta3 integrin MIDAS-like domain affects differently alphavbeta3 and alphaIIIbbeta3 receptor function
66. A β3, integrin mutation abolishes lignad binding and alters divalent cation-dependent conformation
67. Polymorphisms of human platelet membrane glycoproteins: Structure and clinical significance
68. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein. IIb: Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia
69. 214Trp mutation
70. Variant de thrombasthénie Paris-I Lariboisière, anomalie moléculaire du complexe glycoprotéinique plaquettaire IIb-IIIa
71. 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia
72. 3 (platelet glycoprotein IIb-IIIa)
73. Truncation of the cytoplasmic domain of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin αIIbβ3 complex
74. T to Q aminoacid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin αIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome
75. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling
76. Effect of cytoplasmic domain mutations on the agonist-stimulated ligand-binding activity of the platelet integrin αIIbβ3
77. Glycoprotein IIb Leu 214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa
78. DDAVP-induced enhancement of platelet retention: Its dependence on platelet-von Willebrand Factor and the platelet receptor GPIIb/IIIa
79. Severe juvenile vaginal bleeding due to Glanzmann's thrombasthenia; Case report and review of the literature
80. Severe menorrhagia due to Glanzmann thrombasthenia treated with hydrothermal ablation
81. Glanzmann's thrombasthenia in pregnancy: A case and review of the literature
82. Glanzmann's thrombasthenia and pregnancy: Clinical observations and management of four affected women. Congress of the International Society of Thrombosis and Hemostasis
83. Characterization of an antibody to the integrin beta 3 subunit (GPIIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GPIIb-IIIa complexes in platelets (Glanzmann's thrombasthenia)
84. Pregnancy in a patient of Glanzmann's thrombasthenia with antiplatelet antibodies
85. Glanzmann's thrombasthenia and pregnancy. Contribution of plasma exchange before scheduled cesarean section
86. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies
87. Quantification of platelet glycoproteins is a useful index to evaluate platelet transfusion recovery in patients with thrombocytopahies
88. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa
89. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures
90. Thrombotic complications in two patients receiving NovoSeven
91. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
92. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia
93. Five years' experience at once centre with proteinA immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and transplant patients with relapsing focal glomerular sclerosis
94. Complete correction of Glanzmann's thrombasthenia by allogenic bone-marrow transplantation
95. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization
96. Prenatal diagnosis of Glanzmann's thrombasthenia
97. Detection of the Glanzmann's thrombasthenia mutations in Arab and Iraqi-Jewish patients by polymerase chain reaction and restriction analysis of blood and urine samples